# A Phase Ib/II Study of SHR-A1811 Injection in Breast Cancer

> **NCT05353361** · PHASE2 · UNKNOWN · sponsor: **Jiangsu HengRui Medicine Co., Ltd.** · enrollment: 402 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** SHR-A1811：Pyrotinib
- **DRUG:** SHR-A1811；Pertuzumab
- **DRUG:** SHR-A1811；Adebrelimab
- **DRUG:** SHR-A1811；Albumin paclitaxel

## Key facts

- **NCT ID:** NCT05353361
- **Lead sponsor:** Jiangsu HengRui Medicine Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-05-23
- **Primary completion:** 2025-12-31
- **Final completion:** 2025-12-31
- **Target enrollment:** 402 (ESTIMATED)
- **Last updated:** 2023-09-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05353361

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05353361, "A Phase Ib/II Study of SHR-A1811 Injection in Breast Cancer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05353361. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*